

9 **Summary**

10 Brain cancer is the leading cause of cancer-related death in children. Somatic structural
11 variations (SVs), large scale alterations in DNA, remain poorly understood in pediatric brain
12 tumors. Here, we detect a total of 13,199 high confidence somatic SVs in 744 whole-genome-
13 sequenced pediatric brain tumors from Pediatric Brain Tumor Atlas. The somatic SV
14 occurrences have tremendous diversity among the cohort and across different tumor types. We
15 decompose mutational signatures of clustered complex SVs, non-clustered complex SVs, and
16 simple SVs separately to infer the mutational mechanisms of SV formation. Our finding of many
17 tumor types carrying unique sets of SV signatures suggests that distinct molecular mechanisms
18 are active in different tumor types to shape genome instability. The patterns of somatic SV
19 signatures in pediatric brain tumors are substantially different from those in adult cancers. The
20 convergence of multiple signatures to alter several major cancer driver genes suggesting the
21 functional importance of somatic SVs in disease progression.

22

23 **Keywords**

24 Genome instability, genomic rearrangement, chromothripsis, gene fusion

25 Introduction

26 Brain and central nervous system cancers are the most prevalent solid tumors in children under
27 19 and are the leading cause of cancer-related death among children (Ostrom et al., 2015). There
28 are more than 100 types of pediatric brain tumors, which differ markedly from adult brain tumors
29 (Louis et al., 2007). Although the 5-year survival rate of pediatric brain tumors is 75%, the
30 survivors often suffer over their lifetimes from both the disease and the side effects of treatments.
31 Therefore, there is an urgent need to better understand the disease mechanisms and to develop
32 new therapeutic strategies in order to further increase survival and improve the quality of life for
33 patients and their families.

34 Genetic alterations in cancer include single nucleotide variants (SNVs), copy number variants
35 (CNVs), and structural variations (SVs). Pediatric brain tumors have few somatic SNVs, but
36 carry more somatic SVs than other pediatric cancers (Gröbner et al., 2018). SVs are large scale
37 structural changes of DNA such as deletions, tandem duplications, inversions, translocations, and
38 some can be quite complex. For example, chromothripsis refers to a single catastrophic event
39 resulting in numerous SVs through one cell cycle (Maciejowski et al., 2015; Stephens et al.,
40 2011; Zhang et al., 2015). Understanding the mechanisms behind these alterations not only can
41 improve our knowledge of disease biology, but also can reveal therapeutic opportunities. For
42 instance, translocations at the immunoglobulin gene locus in B cell lymphoma are caused by
43 aberrant V(D)J recombination (Alt et al., 2013; Hakim et al., 2012) and often result in activations
44 of *MYC* and *BCL2* oncogenes (Bakhshi et al., 1985; Gostissa et al., 2009). Furthermore, breast
45 and ovarian cancer patients carrying *BRCA1* and *BRCA2* mutations have deficiency in DNA
46 double strand break repair and elevated level of somatic SVs in their tumors (Lee et al., 2016;
47 Nik-Zainal et al., 2016). Patients with BRCA deficiency can be effectively treated by PARP
48 inhibitors (Farmer et al., 2005; Fong et al., 2009). Mutational signatures have been widely used
49 to study the molecular mechanisms of SNVs (Alexandrov et al., 2013, 2020; Degasperis et al.,
50 2022), CNVs (Drews et al., 2022; Steele et al., 2022), SVs (Li et al., 2020) and complex SVs
51 (Bao et al., 2022) in adult cancers. However, comprehensive studies of somatic SV signatures in
52 pediatric brain tumors are still lacking. A recent study of SV signatures in pediatric high-grade
53 glioma has revealed that histone genes, *TP53*, *CDKN2A*, and *RBI* aberrations are associated with
54 complex SVs (Dubois et al., 2022). However, whether other types of pediatric brain tumors
55 harbor similar SV signatures remains unclear.

56 Here, we decompose complex and simple SV signatures from 744 pediatric brain tumors. We
57 find tremendous heterogeneity in SV occurrences and SV signatures across tumor types. We also
58 report that somatic SVs are frequent cancer drivers in pediatric brain tumors.

59

60

61 **Results and Discussion**

62 **High confidence somatic SVs in pediatric brain tumors**

63 Pediatric Brain Tumor Atlas (PBTA) has collected more than 1,000 pediatric brain tumors across
64 more than 30 types. There were 744 samples in PBTA with whole-genome sequencing data after
65 removing non-tumorous lesions, non-brain cancer, and non-primary cancer samples (Table S1).
66 We focused on tumor types with at least 10 samples including: 220 low-grade astrocytic tumors
67 (LGATs), 97 medulloblastomas, 71 ependymomas, 70 high-grade gliomas (HGGs), 44
68 gangliogliomas, 38 craniopharyngiomas, 27 atypical teratoid rhabdoid tumors (ATRTs), 23
69 meningiomas, 23 dysembryoplastic neuroepithelial tumors (DNETs), 17 non-meningothelial
70 mesenchymal tumors, 13 schwannomas, 13 germ cell tumors, 13 neurofibromas, and 12 choroid
71 plexus papillomas. Tumor types with less than 10 samples were all classified as “Others”.

72 A previous study used Manta (Chen et al., 2016) to detect somatic SVs in the PBTA cohort to
73 study the effects of SVs on gene expression (Zhang et al., 2021). However, the quality of
74 variants called by a single algorithm is always not ideal (Campbell et al., 2020). In order to
75 produce high confidence somatic SVs, we integrated three SV calling algorithms: Meerkat (Yang
76 et al., 2013), Manta and Delly (Rausch et al., 2012a). Caller-specific SVs were discarded, and the
77 somatic SVs detected by more than one algorithm were considered as high confidence. Meerkat,
78 Manta and Delly detected 14,423, 55,934 and 9,475 somatic SVs in the 744 samples,
79 respectively (Figure S1A). Since tumor DNA was not available, the SV quality could not be
80 directly measured. Instead, we used CNV breakpoints detected by read depth approach to assess
81 the quality of SVs, since a portion of somatic SVs change DNA copy numbers. We found SVs
82 detected by only one algorithm were not well supported by CNVs (Figure S1B), which suggested
83 that caller-specific SVs had poorer quality. SVs detected by Manta with fewer read pair and split
84 read support were particularly of poor quality (Figure S1C). SVs detected by more than one
85 algorithm were better supported by CNVs (Figure S1B), which suggested that they were of high
86 quality. We also removed deletions that resided at exon-intron boundaries which were likely
87 caused by cDNA contamination (Campbell et al., 2020). As a result, a total of 13,199 high
88 confidence SVs were detected from 744 pediatric brain tumors with a median of 3 SVs per
89 sample. In each type of pediatric brain tumor, the number of somatic SVs per sample varied by
90 nearly three orders of magnitude (Figure 1A). There was also considerable heterogeneity across
91 tumor types. HGGs were most abundant in somatic SVs followed by meningiomas and
92 medulloblastomas, whereas choroid plexus papillomas had no SV at all (Figure 1A). Although
93 most LGATs, ependymomas, gangliogliomas, and neurofibromas had very few SVs, a small
94 fraction of them had very unstable genomes with more than 100 SVs (Figure 1A).

95

96 **Complex SVs in pediatric brain tumors**

97 A non-negative-matrix-factorization-(NMF)-based approach has been very effective in
98 decomposing mutational signatures for somatic SNVs (Alexandrov et al., 2013, 2020; Degasperi
99 et al., 2022) and CNVs (Drews et al., 2022; Steele et al., 2022). Several studies, including the
100 recent SV signature study in pediatric high-grade glioma (Dubois et al., 2022), also used this

101 approach to extract SV signatures by combining both complex SVs and simple SVs (Li et al.,
102 2020). Meaningful signatures can be reliably detected if DNA damage and repair mechanisms
103 generate variants independently and repeatedly in cancer genomes. However, it is well-
104 established that chromothripsis events occur as one-time events and the numbers of SVs vary
105 extensively (Maciejowski et al., 2015; Shoshani et al., 2020; Zhang et al., 2015). Furthermore,
106 multiple molecular mechanisms can lead to chromothripsis. For example, lagging chromosomes
107 trapped in micronuclei during mitosis can shatter into many pieces and some fragments can be
108 ligated together as chromothripsis events (Zhang et al., 2015). Dicentric chromosomes can form
109 chromatin bridges during cell division, shatter into pieces, and also produce chromothripsis
110 (Maciejowski et al., 2015). NMF-based SV signature decomposition cannot differentiate these
111 mechanisms. To better deduce SV signatures in pediatric brain tumors, we studied clustered
112 complex SVs, non-clustered complex SVs and simple SVs separately. Clustered complex SVs
113 are those with breakpoints enriched in certain genomic regions including chromothripsis.
114 Circular extrachromosomal DNA (ecDNA) with many SV breakpoints is also a clustered
115 complex SV (Bao et al., 2022). We recently developed Starfish, a clustering-based approach, to
116 infer clustered complex SV signatures based on their SV and CNV patterns (Bao et al., 2022).
117 We reported six clustered complex SV signatures using nearly 2,500 adult tumors including
118 micronuclei-induced chromothripsis, chromatin-bridge-induced chromothripsis, as well as
119 ecDNA. There are three other signatures that cannot be linked to biological processes, namely
120 “Large loss”, “Large gain” and “Hourglass”. Non-clustered complex SVs are complex SVs with
121 scattered breakpoints including chromoplexy and cycle of templated insertions (Li et al., 2020).
122 Chromoplexy events are likely to form through repair of multiple co-occurring DNA double
123 strand breaks similar to reciprocal translocations (Baca et al., 2013; Berger et al., 2011), whereas
124 templated insertions may reflect replication-based mechanisms (Li et al., 2020; Yang et al.,
125 2013; Zhang et al., 2009). After detecting clustered and non-clustered complex SVs, the
126 remainder of SVs were classified as simple SVs, which include deletions, tandem duplications,
127 balanced/unbalanced/foldback inversions, and balanced/unbalanced translocations.

128 Among the 13,199 SVs in 744 pediatric brain tumors, 7,601 (57.6%) were clustered complex
129 SVs that belonged to 146 individual complex events, 2,377 (18.0%) were non-clustered complex
130 SVs that belonged to 346 events, and 3,221 (24.4%) were simple SVs (Table S2). Out of the 744
131 tumors, 108 (14.5%) and 150 (20.2%) carried clustered and non-clustered complex SVs
132 respectively, whereas 552 (74.2%) did not have any complex SVs. The high numbers of SVs in
133 tumors with very unstable genomes (>100 SVs) were mainly due to their abundance of complex
134 SVs (Figure 1A and Figure S2). HGGs were most abundant in complex SVs, whereas DNETs
135 did not carry any complex SVs (Figure 1A). We used Starfish (Bao et al., 2022) to classify
136 clustered complex SV signatures (Table S3) and used junction pattern (Li et al., 2020) to
137 determine non-clustered complex SVs. HGGs and medulloblastomas carried almost all complex
138 SV signatures, whereas other tumor types only harbored small numbers of complex SV
139 signatures (Figure 1B). The “ecDNA” (Figure 1C) signature was predominantly found in HGGs;
140 the “Large loss” signature (Figure 1C), characterized by complex SVs with large amount of
141 DNA loss, was mainly observed in HGGs and meningiomas; micronuclei-induced
142 chromothripsis (“Micronuclei” signature) (Figure 1C) was enriched in mesenchymal tumors and
143 ependymomas (Figure 1B). Chromatin-bridge-induced chromothripsis (“Chr bridge” signature)

144 (Figure 1C) only occurred in HGGs and neurofibromas (Figure 1B). Hourglass chromothripsis
145 events (“Hourglass” signature), complex SVs with a small amount of DNA loss and highly
146 concentrated SV breakpoints, were detected in a small number of samples in several tumor types
147 (Figure 1B), such as HGGs, meningiomas, medulloblastomas, and ependymomas. Regarding to
148 non-clustered complex SVs, chromoplexy was found in many different tumor types and occurred
149 in as many as 18.6% (13/70) of HGGs and 17.6% (3/17) of mesenchymal tumors (Figure 1D).
150 Cycle of templated insertions was abundant in HGGs (Figure 1D).

151 In summary, different types of pediatric brain tumors often carry distinct complex SV signatures.

152

153 **Simple SVs in pediatric brain tumors**

154 Next, we used the NMF approach to decompose simple SV signatures; a total of nine signatures
155 were extracted (Figure 2A and Table S2). These signatures included deletions smaller than 1kb
156 (“Del0”), deletions between 1kb to 5kb (“Del1”), deletions larger than 5kb (“Del2”), tandem
157 duplications (“TD”), unbalanced inversions (“Unbal inv”), large intra-chromosomal SVs (“Large
158 mixed”), reciprocal inversions and reciprocal translocations (“Recip”), as well as unbalanced
159 translocations (“Unbal tra”). Interestingly, large tandem duplications resulting in *KIAA1549-*
160 *BRAF* fusions belonged to a stand-alone signature, namely “*BRAF* fusion”. HGGs had more
161 simple SVs than other tumor types, while a considerable number of samples from various tumor
162 types, including LGATs and ependymomas, showed no evidence of simple SVs (Figure 2B).
163 Most tumors with simple SVs carried multiple simple SV signatures (Figure 2B), and apparent
164 enrichments could be observed. For example, DNETs predominantly carried the “TD” signature;
165 schwannomas mainly harbored the “Recip” signature; the “Unbal inv” signature was mainly
166 found in HGGs; the “TD” signature was enriched in medulloblastomas; and “Del2” signature
167 was abundant in ATRTs; and the “*BRAF* fusion” signature was almost exclusively observed in
168 LGATs (Figure 2B). Intriguingly, 102 out of 220 LGATs had *KIAA1549-BRAF* fusions, and
169 among the fusion positive LGATs, 88 had only one SV present in their genomes. The SVs
170 producing *KIAA1549-BRAF* fusions were exclusively tandem duplications between 1Mb and
171 2.5Mb in size (Figure 2A).

172 Taken together, our complex SV and simple SV signature analysis demonstrated that numerous
173 mutational mechanisms are active in pediatric brain tumors to induce genome instability, with
174 unique molecular mechanisms present in different tumor types.

175 **Genomic features associated with SV signatures**

176 Somatic SVs are not evenly distributed across the genome (Li et al., 2020). Many factors, such as
177 replication timing, GC content, repeat content, and 3D genome organization, have been
178 associated with SV breakpoint distribution (Akdemir et al., 2020; Li et al., 2020). Here, we
179 surveyed 31 genomic features for their relationships with somatic SVs in pediatric brain tumors
180 (Figure 3).

181 For clustered complex SV signatures, SV breakpoints of the “ecDNA”, “Chr bridge” and “Large
182 gain” signatures were significantly enriched in late replicated regions (Figure 3). In contrast, all

183 clustered complex SV signatures in adult cancers were enriched in early replicated regions (Bao
184 et al., 2022). In adult cancers, all clustered complex SV signatures were enriched in GC-rich
185 regions and near CpG islands (Bao et al., 2022), whereas only the “ecDNA” and “Micronuclei”
186 signatures in pediatric brain tumors were enriched in GC-rich regions (Figure 3). SV breakpoints
187 of the “Large loss” signature were significantly closer to centromeres than expected in pediatric
188 brain tumors (Figure 3), in a pattern opposite to adult cancers (Bao et al., 2022). In adult cancers,
189 the “ecDNA” and “Chr bridge” signatures were significantly farther away from telomeres,
190 whereas other clustered complex SVs were significantly closer to telomeres (Bao et al., 2022).
191 However, all clustered complex SV signatures were significantly closer to telomeres in pediatric
192 brain tumors (Figure 3). All clustered complex SV signatures in adult cancers were significantly
193 closer to many types of repetitive elements (simple repeats, short tandem repeats and
194 transposable elements) (Bao et al., 2022), whereas in pediatric brain tumors, the repetitive
195 elements had variable effects. For example, the “Micronuclei” signature in pediatric brain tumors
196 were enriched near Alu elements but depleted around L1s (Figure 3). Therefore, the SV
197 breakpoint distributions of clustered complex SVs in pediatric brain tumors were quite different
198 from those of adult cancers.

199 Chromoplexy was proposed to form similar to reciprocal translocations through simultaneous
200 ligation of multiple broken chromosomal ends (Baca et al., 2013; Berger et al., 2011). In adult
201 cancers, chromoplexy breakpoints and reciprocal translocations shared similar patterns. For
202 example, they were both enriched in late replicated regions. In sharp contrast, chromoplexy
203 breakpoints in pediatric brain tumors were enriched in early replicated regions while reciprocal
204 translocations did not display any bias in replication timing (Figure 3). In addition, chromoplexy
205 breakpoints in pediatric brain tumors were also enriched in GC-rich regions and near telomeres,
206 while reciprocal translocations were enriched in AT-rich regions and not enriched towards either
207 centromeres or telomeres (Figure 3). These results suggested that chromoplexy in pediatric brain
208 tumors may form through a different mechanism than reciprocal translocations. Cycle of
209 templated insertion breakpoints in pediatric brain tumors had little association with most
210 genomic features except for proximity to telomeres (Figure 3).

211 Simple SV breakpoint distributions of pediatric brain tumors were also quite distinct from those
212 of adult cancers. In adult cancers, deletions were enriched in early replicated regions, and tandem
213 duplications and unbalanced translocations were enriched in late replicated regions (Li et al.,
214 2020). In contrast, in pediatric brain tumors, smaller deletions (“Del0” and “Del1”) were not
215 associated with replication timing, large deletions (“Del2”) were enriched in late replicated
216 regions, and tandem duplications (“TD”) as well as unbalanced translocations (“Unbal tra”) were
217 enriched in early replicated regions (Figure 3). In adult cancers, all deletions regardless of their
218 sizes were enriched in AT-rich regions (Li et al., 2020); whereas in pediatric brain tumors, small
219 deletions (“Del1”) were enriched in GC-rich regions and large deletions (“Del2”) were enriched
220 in AT-rich regions (Figure 3). In adult cancers, tandem duplications were significantly closer to
221 Alu elements (Li et al., 2020); whereas in pediatric brain tumors, tandem duplications (“TD”) were
222 farther away from L1s, LTR transposons, and DNA transposons (Figure 3). In adult
223 cancers, both small and large deletions were depleted from topologically associated domain
224 (TAD) boundaries (Li et al., 2020). However, in pediatric brain tumors, only large deletions

225 (“Del2”), but not small deletions (“Del0” and “Del1”), were depleted from TAD boundaries
226 (Figure 3).

227 Taking the above results together, our results suggest that the forming mechanisms of somatic
228 SVs, both complex and simple SVs, in pediatric brain tumors were likely to be different from
229 those of adult cancers.

230 Next, we sought to identify mutations associated with genome instability. As expected, *TP53*
231 mutations in HGGs were associated with “Chr bridge” and “Large loss”, and cycle of templated
232 insertions, as well as six simple SV signatures: “Unbal inv”, “Unbal tra”, “Large mixed”, “TD”,
233 “Del1” and “Del2” (Figure S3). In addition, *H3F3A* mutations in HGGs were associated with
234 cycle of templated insertions (Figure S3) suggesting that histones may play important roles in
235 genome instability in pediatric brain tumors. *ATRX* mutations in HGGs were associated with
236 “Large mixed” signatures (Figure S3). No other mutations were associated with any SV
237 signatures in any other pediatric brain tumors. In adult cancers, small deletions are associated
238 with *BRCA2* mutations, and small and large tandem duplications are associated with *BRCA1* and
239 *CDK12* mutations (Li et al., 2020; Nik-Zainal et al., 2016). In the 741 non-hypermutated
240 pediatric brain tumors, only one sample carried a *BRCA1* mutation, and another sample carried a
241 *BRCA2* mutation. This again suggested that the mechanisms of formation of deletions and
242 tandem duplications in pediatric brain tumors are likely to be different from those of adult
243 cancers.

244

245 **SV breakpoint sequences**

246 We then investigated microhomology and insertion sequences at the SV breakpoints across SV
247 signatures. SVs are the results of erroneous repair of DNA double strand breaks or replication
248 errors. Various repair pathways are involved (Aguilera and García-Muse, 2013; Bunting and
249 Nussenzweig, 2013), such as non-homologous end joining (NHEJ), alternative end joining (alt-
250 EJ), and microhomology-mediated break-induced repair (MMBIR). NHEJ usually ligates blunt
251 DNA ends or ends with short 1-4bp homology. Alt-EJ often uses slightly longer homology for
252 repair. MMBIR is considered a replication based template switching mechanism and non-
253 template insertions are frequently present at the breakpoints (Zhang et al., 2009). Several SV
254 signatures in pediatric brain tumors, including “Large loss”, “Hourglass”, chromoplexy, and
255 “Unbal tra”, had a majority of SV breakpoints being blunt DNA ends (no homology nor insertion
256 at the breakpoints) (Figure 4). This suggested that these SVs are likely to form through NHEJ.
257 Some other signatures, such as “Chr bridge”, “Micronuclei”, “Del0”, “Del1”, “Unbal inv”, and
258 “Large mixed”, had slightly longer homology at the breakpoints with 1bp microhomology being
259 the most frequent and also consistent with NHEJ (Figure 4). In addition, “TD”, “Recip”, and
260 “*BRAF* fusion” signatures had 2bp microhomology being the most frequent (Figure 4) suggesting
261 alt-EJ might play more important roles in these SVs. The observation of extended
262 microhomology in the “Recip” signature was consistent with breakpoints found in the
263 Philadelphia chromosome, the most prevalent reciprocal translocation in leukemia, often
264 involving 2-8 bp microhomology (McVey and Lee, 2008). Although previous studies proposed

265 that chromoplexy forms in a manner similar to reciprocal translocation (Baca et al., 2013; Berger
266 et al., 2011), our observation of chromoplexy and reciprocal translocation breakpoints with
267 different microhomology patterns suggested that they may form via different mechanisms.
268 Furthermore, a fraction of SVs in “Del1” had 5 bp or longer microhomology (Figure 4)
269 especially in ependymomas, suggesting alt-EJ being the dominant mechanism in ependymoma.
270 Intriguingly, “ecDNA” and “Large gain” signatures had frequent inserted sequences that were
271 more than 10 bp (Figure 4), suggesting possible involvement of replication-based mechanisms
272 such as MMBIR.

273

274 **SV hotspots and tumor drivers**

275 Hotspots of SV breakpoints often represent genetic alterations under positive selection and genes
276 driving diseases. After binning the reference genome into 1 Mb window and counting SV
277 occurrences, we found different SV signatures having quite distinct hotspots. *MYCN* and *MYC*
278 are two frequently amplified oncogenes in pediatric brain tumors (Dubois et al., 2022).
279 Interestingly, *MYCN* was amplified exclusively by “ecDNA” in HGGs and exclusively by
280 “Large gain” in medulloblastomas (Figure 5), since “ecDNA” and “Large gain” were the most
281 abundant clustered complex SV signatures in HGGs and medulloblastomas, respectively. Both
282 signatures converged on *MYCN* amplifications, which are the main oncogenic events in HGGs
283 and medulloblastomas. *MYCN* was also amplified by non-clustered complex SV with unclear
284 pattern (“Complex unclear”) in various tumor types (Figure 5). Tandem duplications can also
285 amplify DNA. However, *MYCN* was not amplified by the “TD” signature in any samples,
286 whereas *MYC* was amplified by the “TD” signature in a few HGGs and medulloblastomas
287 (Figure 5). In addition, *FGFR1* was frequently amplified by the “TD” signature in DNETs
288 (Figure 5). DNETs had very few somatic SVs and did not carry any clustered or non-clustered
289 complex SVs. “TD” was the dominant SV signature in DNETs. These findings suggested that
290 “TD” and *FGFR1* amplifications were the major oncogenic events in DNETs. Furthermore,
291 chromoplexy and “Del2” frequently disrupted *CDKN2A* in various tumor types (Figure 5). The
292 “*BRAF* fusion” signature produced *KIAA1549-BRAF* fusions mainly in LGATs (Figure 5). The
293 “Recip” signature often led to *EWSR1* fusions in various tumor types (Figure 5).

294 Interestingly, multiple SV signatures harbored hotspots on chromosome 11, and the hotspots
295 were only found in ependymomas (Figure 5). *C11orf95-RELA* fusions are the major oncogenic
296 events in 70% of supratentorial ependymomas (Parker et al., 2014). Recently, the World Health
297 Organization (WHO) recommended the use of the *ZFTA (C11orf95)* fusion to classify
298 supratentorial ependymoma instead of the *RELA* fusion because *ZFTA* can fuse to other partners
299 as well (Louis et al., 2021). There were 71 ependymomas in our cohort and 23 of them (32%)
300 were supratentorial (Figure 6A and Table S4). Among them, 13 (57%) carried *ZFTA* fusions
301 (Figure 6A). There were 2 other *ZFTA* fusion positive ependymomas classified as “Others”
302 (Figure 6A). Twelve out of 15 *ZFTA* fusions were driven by complex SVs and three were driven
303 by tandem duplications (“TD”) (Figure 6A). Among the 12 fusions resulting from complex
304 events, 5 were micronuclei-induced chromothripsis (“Micronuclei”), 3 were hourglass
305 chromothripsis (“Hourglass”), and 4 were non-clustered complex SVs (Figure 6A and 6B). Some

306 of the complex SVs involved the entire chromosome 11 (BS_K6A9Z04J), whereas others only
307 affected a small region in chromosome 11 (BS_NWYBD9CA) (Figure 6B). These results
308 showed that there are diverse mechanisms generating genome instability in ependymomas and
309 they have shared oncogenic consequence of forming *ZFTA* fusions. The most prevalent complex
310 SVs in ependymomas were micronuclei-induced chromothripsis events caused by erroneous
311 chromosomal segregation. It is possible that the frequent complex SVs in ependymomas are due
312 to frequent chromosomal segregation errors. However, aneuploidy is rare in ependymomas
313 (Mack and Taylor, 2017). This suggested that chromosomal segregation errors are likely not
314 frequent events in ependymomas, and complex SVs in ependymomas are under positive
315 selection. Furthermore, since tandem duplications are sufficient to produce gene fusions, such as
316 *ZFTA* fusions and *BRAF* fusions, and the fact that most somatic SVs in ependymomas involving
317 chromosome 11 were complex SVs suggested that other genes altered by SVs may contribute to
318 ependymoma tumorigenesis as well. “Unbal inv” signature also had a hotspot in a similar region
319 on chromosome 11 (Figure 5). Three ependymomas had unbalanced inversions in gene *MARK2*,
320 which is next to *ZFTA*, and no fusions were formed. Whether this “Unbal inv” hotspot in
321 ependymoma reflects oncogenic events remains unclear.

322 In a significant fraction of pediatric brain tumors, the disease-causing SVs were the sole SVs of
323 the corresponding signatures. These signatures did not produce additional passenger SVs in those
324 samples. For example, 88 LGATs were driven by *BRAF* fusions and there was only one SV
325 within the “*BRAF* fusion” signature in those samples (Figure 2B). Similarly, three ependymomas
326 carried *ZFTA* fusions caused by the “TD” signature, and there was only one SV within the “TD”
327 signature in two of these three samples (Figure 2B and Figure 5). In addition, nine DNETs had
328 *FGFR1* amplifications resulting from the “TD” signature, and there was only one SV within the
329 “TD” signature in all nine samples (Figure 2B and Figure 5). These results indicated that the
330 molecular mechanisms leading to these disease-driving SVs are not highly active in tumor
331 initiating cells. Cells independently acquire SVs through these mechanisms at very low rates, and
332 cells that have acquired SVs that alter the major disease-driving genes eventually outcompete
333 other cells and become tumors.

334

335 **Impact of SVs on patient survival**

336 Next, we sought to evaluate whether somatic SVs affect patient survival in pediatric brain
337 tumors. Chromothripsis has been associated with worse patient survival in several previous
338 studies (Cortés-Ciriano et al., 2020; Molenaar et al., 2012; Notta et al., 2016; Rausch et al.,
339 2012b). However, we did not observe any complex SV signatures associated with patient
340 survival in HGGs, LGATs, medulloblastomas or ependymomas (Figure S4). HGG patients with
341 “Del2” and “Unbal tra” signatures in their tumors had significantly worse survival, and those
342 with “Del1” and “Large mixed” signatures had marginally worse survival (Figure 7). HGGs were
343 most abundant in simple SVs, which suggested that the SV forming mechanisms are relatively
344 more active in tumor initiating cells of HGGs than those of other tumor types. No simple SV
345 signatures were associated with patient survival in other tumor types. It is possible that simple

346 SV forming mechanisms are not very active in tumor types other than HGGs; therefore simple
347 SV signatures are associated with patient survival only in HGGs.
348

349 **Acknowledgement**

350 We thank the Center for Research Informatics at the University of Chicago for providing the
351 computing infrastructure. We thank Dr. Ji Won Lee for assistance in tumor pathology. The work
352 was supported by the National Institutes of Health grant R03CA246228 (L.Y.).

353 **Author contributions**

354 L.Y. conceptualized the study. Y.Y. developed the analysis workflow and performed the
355 analysis. Y.Y. and L.Y. interpreted the results. L.Y. supervised the study. L.Y. wrote the paper.
356 All authors have read and approved the final manuscript.

357

358 **Declaration of interests**

359 The authors have no competing interests to declare.

360

361 **Figure Legends**

362 **Figure 1 Somatic SVs and complex SVs in 744 pediatric brain tumors.** (A) Frequencies of
363 somatic SVs and percentages of different types of SVs. In the upper panel, each dot represents
364 one pediatric brain tumor sample. Samples are grouped by tumor type and tumor types are sorted
365 by median SV frequency (red lines) except for the “Others” category. The numbers in
366 parentheses are sample sizes for the corresponding tumor types. The bottom panel shows the
367 percentages of clustered complex SVs, non-clustered complex SVs, and simple SVs in the
368 corresponding samples on the top panel. HGG: high-grade glioma. ATRT: atypical
369 teratoid/rhabdoid tumor. LGAT: low-grade astrocytic tumor. DNET: dysembryoplastic
370 neuroepithelial tumor. (B) and (D) Percentages of clustered complex SV signatures and non-
371 clustered complex SVs. Each vertical block represents one tumor type and each horizontal bar
372 represent one sample. Samples are colored based on their SV signatures. Samples carry multiple
373 signatures have multiple colors arranged horizontally. The height of each sample may differ
374 across tumor types depending on sample sizes of the tumor types. (C) Examples of clustered
375 complex SVs. Colored arcs represent SVs of different types. The red bars below the SVs indicate
376 regions of clustered complex SVs. Copy number profiles are displayed by black bars above the
377 chromosome models. The red bars within the grey chromosome models indicate the locations of
378 centromeres. Tumor types and sample IDs are shown next to the names of clustered complex SV
379 signatures. DEL: deletion, DUP: tandem duplication, h2hINV: head to head inversion, t2tINV:
380 tail to tail inversion, TRA: translocation.

381 **Figure 2 Simple SV signatures and their distributions.** (A) Nine simple SV signatures of 744
382 pediatric brain tumors. The four major SV categories and 49 subcategories of simple SVs are
383 shown on the y axis. The names of the nine simple SV signatures are displayed on the top. The
384 relative contributions of SV subcategories to the corresponding signatures are shown on the x
385 axis. (B) Frequencies of simple SVs and percentages of simple SV signatures. In the upper panel,
386 each dot represents one sample. Samples are grouped by tumor types. Red bars indicate median
387 frequencies. The numbers in parentheses are sample sizes for the corresponding tumor types. The
388 bottom panel shows the percentages of simple SV signatures in the corresponding samples on the
389 top panel.

390 **Figure 3 Associations of SV signatures with 31 genomic features.** SV signatures and genomic
391 features are listed in the x and y axes respectively. Each dot represents the association between
392 one SV signature and one genomic feature. The bigger the dots are, the more significant the
393 associations are. The colors of the dots indicate the directions of median shift. The directions of
394 biases are shown in the parentheses of genomic features. For instance, the “ecDNA” signature
395 has red color (left on the color key) dot for centromere, indicating that the observed SV
396 breakpoints of this signature are farther away (left in the parentheses) from centromeres than
397 randomized breakpoints.

398 **Figure 4 SV breakpoint homology.** The distributions (x axis) of homology and insertion at SV
399 breakpoints are shown for all SV signatures (y axis). The putative DNA repair mechanisms are
400 inferred from the sizes of homology and insertion and annotated next to the signatures. The bars
401 indicate number of somatic SVs and are colored by tumor type. MMBIR: microhomology-

402 mediated break-induced repair. NHEJ: non-homologous end joining. alt-EJ: alternative end
403 joining.

404 **Figure 5 SV breakpoint hotspots.** SV breakpoint frequencies are shown for the entire reference
405 genome (x axis) across different SV signatures (y axis). Chromosome models are shown as grey
406 bars with red lines indicating locations of centromeres at the bottom. Hotspots containing known
407 oncogenes, tumor suppressors, and fragile sites are annotated.

408 **Figure 6 ZFTA fusions in ependymomas.** (A) The prevalence of *ZFTA* fusions in 71
409 ependymomas. Samples are colored by signatures of the SVs resulting in *ZFTA* fusions and
410 ependymoma subtypes. (B) Six examples of *ZFTA* fusions resulting from different SV
411 signatures. SV signatures and sample IDs are shown on the top. Somatic SVs, regions of
412 complex SVs and copy number profiles are displayed in the same scheme as Figure 1C. The
413 *ZFTA* and *RELA* regions are zoomed in and *ZFTA* gene and *RELA* gene are further zoomed in
414 respectively. Gene structures are shown at the bottom of six examples. Within gene structures,
415 the SV breakpoints that lead to *ZFTA-RELA* fusions are shown as red vertical lines. The
416 directions of gene transcription are indicated by arrows.

417 **Figure 7 SV signatures associated with patient survival.** Kaplan-Meier survival curves for
418 HGG patients, stratified by the presence or absence of four simple SV signatures (“Del2”,
419 “Unbal tra”, “Del1”, and “Large mixed”) are shown. P values are calculated by log-rank test.

420 **STAR Methods**

421 **Sample and data collection**

422 The raw normal and tumor whole-genome sequencing data for 744 pediatric brain tumor patients
423 were downloaded from CAVATICA (<https://cavatica.sbgenomics.com/>). Sample characteristics,
424 clinical data, somatic SNV, and somatic CNV data were retrieved from OpenPBTA GitHub
425 (<https://github.com/AlexsLemonade/OpenPBTA-analysis>,
426 <https://www.biorxiv.org/content/10.1101/2022.09.13.507832v1>). All patients were de-identified.

427 Gene annotation was obtained from ENSEMBL (GRCh38.p13)
428 (<https://useast.ensembl.org/index.html>). Non-B DNA structures including A-phased repeats,
429 direct repeats, G-quadruplex forming repeats, inverted repeats, mirror repeats, short tandem
430 repeats and Z-DNA motifs were downloaded from non-B DB (Cer et al., 2013) ([https://nonb-
431 abcc.ncifcrf.gov/apps/nBMST/default/](https://nonb-abcc.ncifcrf.gov/apps/nBMST/default/)); Alu, L1, L2, LTR, MIR, simple repeat, transposon, and
432 low complexity repetitive elements, as well as the coordinates of centromeres, telomeres, and
433 CpG islands, were obtained from UCSC
434 (<https://hgdownload.soe.ucsc.edu/goldenPath/hg38/database/>); consensus estimate of the
435 topologically associated domains (TADs) were downloaded from TAD Map (Singh and Berger,
436 2021) (<https://cb.csail.mit.edu/cb/tadmap/>); ChIP-seq data of epigenetic markers H3K4me1,
437 H3K9me3, H3K36me3, H3K4me3, H3K27me3, H3K9ac, H3K4me2, H3K79me2, H3K27ac,
438 and H4K20me1 from human astrocyte were downloaded from ENCODE (Zhang et al., 2020)
439 (<https://www.encodeproject.org/>). The Wavelet-smoothed signal of replication timing data for
440 the cell lines BG02ES and SK-N-SH were downloaded from UCSC
441 (<https://genome.ucsc.edu/cgi-bin/hgFileUi?db=hg19&g=wgEncodeUwRepliSeq>). The fragile
442 site regions were obtained from a previous study (Li et al., 2020), and the coordinates were lifted
443 over to hg38. All coordinates in this study were based on the hg38 genome assembly unless
444 otherwise noted.

445 **Tumor classifications**

446 The histological classifications of tumor samples were determined based on diagnosis,
447 pathological examination, and histological examination according to the 2021 WHO
448 classifications of pediatric brain tumors (Louis et al., 2021). For tumor types with at least 10
449 samples, we attempted to subclassify them. Gliomas were subclassified into high-grade gliomas
450 (HGGs), low-grade astrocytic tumors (LGATs), ependymomas, dysembryoplastic neuroepithelial
451 tumors (DNETs), and gangliogliomas. Embryonal tumors were subclassified into
452 medulloblastomas, and atypical teratoid rhabdoid tumors (ATRTs). Cranial and paraspinal nerve
453 tumors included schwannomas and neurofibromas. Germ cell tumors included teratomas,
454 germinomas, and other germ cell tumors. Mesenchymal non-meningothelial tumors included
455 hemangioblastomas, Ewing sarcomas, rhabdomyosarcomas, myofibroblastomas, and other
456 sarcomas. Meningiomas, craniopharyngiomas, and choroid plexus tumors were independently
457 classified. Tumor types with less than 10 samples were all classified into “Others”.
458 Ependymomas were further stratified into distinct subtypes based on the primary sites.

459 **Somatic SV calling and filtering**

460 Manta (<https://github.com/Illumina/manta>), Meerkat (<https://github.com/guru-yang/Meerkat>),
461 and Delly (<https://github.com/dellytools/delly>) were used for somatic SV detection. SVs called
462 by Manta were obtained from OpenPBTA. Meerkat was run as suggested (Yang et al., 2013).
463 Delly was run with default settings. For SVs detected by Delly, at least four supporting read pairs
464 and split read combined were required for SVs less than 500 bp. For all three SV detection
465 algorithms, only SVs located in canonical chromosomes (chr1-22, X, Y) were retained. SVs
466 identified by different algorithms were considered identical if their two breakpoints were on the
467 same chromosomes, with the same orientations and within 10 bp. SVs identified by two or more
468 algorithms were considered high-confidence SVs and used in the subsequent analysis. Deletions
469 with both breakpoints within 3 bp of exon-intron boundaries of the same genes were excluded
470 from further analysis.

471 Somatic CNVs were used to assess the quality of somatic SVs. For each SV, if the distances of
472 both SV breakpoints were less than 1 kb to the nearest CNV breakpoints, the SV was considered
473 validated.

474 **Complex SVs and their signatures**

475 We used Starfish (Bao et al., 2022) (<https://github.com/yanglab-computationalgenomics/Starfish>)
476 to detect clustered complex SVs and classified them into six signatures. In cases where reported
477 gender and germline estimated sex were inconsistent, gender identity was recorded as unknown
478 for signature detection. After removing clustered complex SVs, we used ClusterSV (Li et al.,
479 2020) (<https://github.com/cancerit/ClusterSV>) to identify non-clustered complex SVs. Non-
480 clustered complex SVs include chromoplexy, cycle of templated insertions, and complex
481 unclear.

482 **Simple SV signatures**

483 After removing clustered and non-clustered complex SVs, the remainder were simple SVs
484 including four major categories: deletions, tandem duplications, inversions, and translocations.
485 Deletions and tandem duplications with breakpoints falling within fragile site regions were
486 classified as fragile site deletions and fragile site tandem duplications, respectively. The
487 remaining deletions and tandem duplications were classified into 18 subcategories based on their
488 sizes. Inversions and translocations were further subclassified into reciprocal inversions, fold-
489 back inversions, unbalanced inversions, reciprocal translocations, and unbalanced translocations.
490 Unbalanced inversions and reciprocal inversions were classified into 3 and 5 subcategories based
491 on their sizes, respectively. Fold-back inversions, unbalanced translocations, and reciprocal
492 translocations were three independent subcategories. As a result, all simple SVs were classified
493 into 49 subcategories and SigProfilerExtractor (Islam et al., 2022)
494 (<https://github.com/AlexandrovLab/SigProfilerExtractor>) with default parameters was used to
495 extract simple SV signatures. According to the final signatures we chose, deletions smaller than
496 1kb were assigned as “Del0”; deletions ranging in size from 1kb-5kb were classified as “Del1”;
497 fragile site deletions, fragile site tandem duplications, and deletions sized in 5kb-10Mb were
498 assigned as “Del2”; tandem duplications between 1Mb-2.5Mb with breakpoints located within
499 the *BRAF* region were classified as *BRAF* fusion signature; other tandem duplications were

500 classified as “TD”; foldback inversions and unbalanced inversions sized between 50kb-5Mb
501 were categorized as “Unbal inv”; deletions and tandem duplications larger than 10Mb, as well as
502 reciprocal unbalanced inversions larger than 5Mb, were classified as “Large mixed”; reciprocal
503 inversions and reciprocal translocations were categorized as “Recip”; and unbalanced
504 translocations were classified as “Unbal tra”.

505 **Genomic feature tests**

506 For each observed somatic SV, we generated four random SVs on the same chromosome, same
507 size, and same type. All observed and randomized breakpoints were annotated with genomic
508 features. Bedtools was used to compute the GC content within a ± 50 bp interval of each SV
509 breakpoint. The distances in kilobases (kb) from the breakpoints to the nearest Non-B DNA
510 structures, repetitive elements, and CpG islands were logarithmically transformed, with the
511 distances set to 0 if breakpoints were within any of the aforementioned elements. The distances
512 in megabases (Mb) from the breakpoints to centromeres and telomeres and the distances (kb) to
513 the closest TAD boundaries were also transformed to log scale. The SV breakpoints were
514 annotated by signal $-\log_{10}(\text{p-values})$ for different epigenetic modifications. The replication
515 timing data for cell lines BG02ES and SK-N-SH were quantile normalized. The SV breakpoints
516 were lifted over to hg19 since the replication timing data were based on hg19. The replication
517 timing values were then annotated for each SV breakpoint. Breakpoints of observed SVs and
518 randomized SVs were tested as described in the previous study (Li et al., 2020). Briefly, scores
519 of SV breakpoints for all genomic features were rescaled from 0 to 1. The distributions of scores
520 between observed breakpoints and randomized breakpoints were compared using two-sided
521 Kolmogorov-Smirnov test. False discovery rates (FDRs) were computed using the Benjamini-
522 Hochberg procedure and 0.1 FDR cutoff was used to determine significant associations.
523 Homology and insertion size at the SV breakpoints were provided by Meerkat and Manta.

524 **Hotspot analysis**

525 The reference genome was divided into 1Mb non-overlapping bins. The number of samples with
526 SV breakpoints in each bin was counted for each SV signature. A sample with multiple SV
527 breakpoints of the same SV signatures falling within the same bin was only counted once.

528 **Mutation test**

529 Only protein-altering somatic SNVs and indels were considered, including missense mutations,
530 splice site mutations, frameshift indels, nonsense mutations, translation start site mutations, and
531 nonstop mutations. Three HGG samples (BS_20TBZG09, BS_02YBZSBY, and
532 BS_VW4XN9Y7) with hypermutation were excluded. The tests were performed within tumor
533 types. Protein-coding genes with mutation frequencies $\geq 5\%$ in each tumor type were analyzed.
534 Samples were classified into two categories based on the presence and absence of the SV
535 signatures. Fisher’s exact test was used to calculate p values. FDRs were computed using the
536 Benjamini-Hochberg procedure. $\text{FDR} < 0.1$ was considered as significant.

537 **Survival analysis**

538 Since patient survival differs dramatically across tumor types, survival analysis was only
539 performed within tumor types, but not across tumor types. For clustered complex SV signatures,
540 samples with only one signature were assigned to the corresponding signatures; samples with
541 more than one clustered complex SV signatures were classified into “Mixed”; and samples
542 without any clustered complex SV were assigned into “None”. For simple SV signatures,
543 samples were classified based on the presence and absence of the signatures. Log-rank test was
544 used to calculate p values.




545 **References**



- 546 Aguilera, A., and García-Muse, T. (2013). Causes of genome instability. *Annu. Rev. Genet.* *47*,
547 1–32.
- 548 Akdemir, K.C., Le, V.T., Chandran, S., Li, Y., Verhaak, R.G., Beroukhim, R., Campbell, P.J.,
549 Chin, L., Dixon, J.R., Futreal, P.A., et al. (2020). Disruption of chromatin folding domains by
550 somatic genomic rearrangements in human cancer. *Nat. Genet.* *52*, 294–305.
- 551 Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A.J.R., Behjati, S., Biankin, A. V.,
552 Bignell, G.R., Bolli, N., Borg, A., Børresen-Dale, A.-L., et al. (2013). Signatures of mutational
553 processes in human cancer. *Nature* *500*, 415–421.
- 554 Alexandrov, L.B., Kim, J., Haradhvala, N.J., Huang, M.N., Tian Ng, A.W., Wu, Y., Boot, A.,
555 Covington, K.R., Gordenin, D.A., Bergstrom, E.N., et al. (2020). The repertoire of mutational
556 signatures in human cancer. *Nature* *578*, 94–101.
- 557 Alt, F.W., Zhang, Y., Meng, F.L., Guo, C., and Schwer, B. (2013). Mechanisms of programmed
558 DNA lesions and genomic instability in the immune system. *Cell* *152*, 417–429.
- 559 Baca, S.C., Prandi, D., Lawrence, M.S., Mosquera, J.M., Romanel, A., Drier, Y., Park, K.,
560 Kitabayashi, N., MacDonald, T.Y., and Ghandi, M. (2013). Punctuated evolution of prostate
561 cancer genomes. *Cell* *153*, 666–677.
- 562 Bakhshi, A., Jensen, J.P., Goldman, P., Wright, J.J., McBride, O.W., Epstein, A.L., and
563 Korsmeyer, S.J. (1985). Cloning the chromosomal breakpoint of t(14;18) human lymphomas:
564 clustering around Jh on chromosome 14 and near a transcriptional unit on 18. *Cell* *41*, 899–906.
- 565 Bao, L., Zhong, X., Yang, Y., and Yang, L. (2022). Starfish infers signatures of complex
566 genomic rearrangements across human cancers. *Nat. Cancer* *2022* *3*, 1247–1259.
- 567 Berger, M.F., Lawrence, M.S., Demichelis, F., Drier, Y., Cibulskis, K., Sivachenko, A.Y.,
568 Sboner, A., Esgueva, R., Pflueger, D., Sougnez, C., et al. (2011). The genomic complexity of
569 primary human prostate cancer. *Nature* *470*, 214–220.
- 570 Bunting, S.F., and Nussenzweig, A. (2013). End-joining, translocations and cancer. *Nat. Rev.*
571 *Cancer* *13*, 443–454.
- 572 Campbell, P.J., Getz, G., Korbel, J.O., Stuart, J.M., Jennings, J.L., Stein, L.D., Perry, M.D.,
573 Nahal-Bose, H.K., Ouellette, B.F.F., Li, C.H., et al. (2020). Pan-cancer analysis of whole
574 genomes. *Nature* *578*, 82–93.
- 575 Cer, R.Z., Donohue, D.E., Mudunuri, U.S., Temiz, N.A., Loss, M.A., Starner, N.J., Halusa, G.N.,
576 Volfovsky, N., Yi, M., Luke, B.T., et al. (2013). Non-B DB v2.0: a database of predicted non-B
577 DNA-forming motifs and its associated tools. *Nucleic Acids Res.* *41*.
- 578 Chen, X., Schulz-Trieglaff, O., Shaw, R., Barnes, B., Schlesinger, F., Källberg, M., Cox, A.J.,
579 Kruglyak, S., and Saunders, C.T. (2016). Manta: rapid detection of structural variants and indels
580 for germline and cancer sequencing applications. *Bioinformatics* *32*, 1220–1222.
- 581 Cortés-Ciriano, I., Lee, J.J.-K., Xi, R., Jain, D., Jung, Y.L., Yang, L., Gordenin, D., Klimczak,
582 L.J., Zhang, C.-Z., Pellman, D.S., et al. (2020). Comprehensive analysis of chromothripsis in


- 583 2,658 human cancers using whole-genome sequencing. *Nat. Genet.* 52, 331–341.
- 584 Degasperi, A., Zou, X., Amarante, T.D., Martinez-Martinez, A., Koh, G.C.C., Dias, J.M.L.,
585 Heskin, L., Chmelova, L., Rinaldi, G., Wang, V.Y.W., et al. (2022). Substitution mutational
586 signatures in whole-genome–sequenced cancers in the UK population. *Science* 376.
- 587 Drews, R.M., Hernando, B., Tarabichi, M., Haase, K., Lesluyes, T., Smith, P.S., Morrill Gavarró,
588 L., Couturier, D.L., Liu, L., Schneider, M., et al. (2022). A pan-cancer compendium of
589 chromosomal instability. *Nature* 606, 976–983.
- 590 Dubois, F.P.B., Shapira, O., Greenwald, N.F., Zack, T., Wala, J., Tsai, J.W., Crane, A., Baguette,
591 A., Hadjadj, D., Harutyunyan, A.S., et al. (2022). Structural variants shape driver combinations
592 and outcomes in pediatric high-grade glioma. *Nat. Cancer* 2022 38 3, 994–1011.
- 593 Farmer, H., McCabe, H., Lord, C.J., Tutt, A.H.J., Johnson, D.A., Richardson, T.B., Santarosa,
594 M., Dillon, K.J., Hickson, I., Knights, C., et al. (2005). Targeting the DNA repair defect in
595 BRCA mutant cells as a therapeutic strategy. *Nature* 434, 917–921.
- 596 Fong, P.C., Boss, D.S., Yap, T.A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P.,
597 Swaisland, H., Lau, A., O’Connor, M.J., et al. (2009). Inhibition of Poly(ADP-Ribose)
598 Polymerase in Tumors from BRCA Mutation Carriers. *N. Engl. J. Med.* 361, 123–134.
- 599 Gostissa, M., Yan, C.T., Bianco, J.M., Cogné, M., Pinaud, E., and Alt, F.W. (2009). Long-range
600 oncogenic activation of Igh-c-myc translocations by the Igh 3’ regulatory region. *Nature* 462,
601 803–807.
- 602 Gröbner, S.N., Worst, B.C., Weischenfeldt, J., Buchhalter, I., Kleinheinz, K., Rudneva, V.A.,
603 Johann, P.D., Balasubramanian, G.P., Segura-Wang, M., Brabetz, S., et al. (2018). The landscape
604 of genomic alterations across childhood cancers. *Nature* 555, 321–327.
- 605 Hakim, O., Resch, W., Yamane, A., Klein, I., Kieffer-Kwon, K.R., Jankovic, M., Oliveira, T.,
606 Bothmer, A., Voss, T.C., Ansarah-Sobrinho, C., et al. (2012). DNA damage defines sites of
607 recurrent chromosomal translocations in B lymphocytes. *Nature* 484, 69–74.
- 608 Islam, S.M.A., Díaz-Gay, M., Wu, Y., Barnes, M., Vangara, R., Bergstrom, E.N., He, Y., Vella,
609 M., Wang, J., Teague, J.W., et al. (2022). Uncovering novel mutational signatures by de novo
610 extraction with SigProfilerExtractor. *Cell Genomics* 0, 100179.
- 611 Lee, J.-K., Choi, Y.-L., Kwon, M., and Park, P.J. (2016). Mechanisms and Consequences of
612 Cancer Genome Instability: Lessons from Genome Sequencing Studies. *Annu. Rev. Pathol.*
613 *Mech. Dis.* 11, 283–312.
- 614 Li, Y., Roberts, N.D., Wala, J.A., Shapira, O., Schumacher, S.E., Kumar, K., Khurana, E.,
615 Waszak, S., Korbil, J.O., Haber, J.E., et al. (2020). Patterns of somatic structural variation in
616 human cancer genomes. *Nature* 578, 112–121.
- 617 Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K., Burger, P.C., Jouvet, A., Scheithauer,
618 B.W., and Kleihues, P. (2007). The 2007 WHO classification of tumours of the central nervous
619 system. *Acta Neuropathol.* 114, 97–109.
- 620 Louis, D.N., Perry, A., Wesseling, P., Brat, D.J., Cree, I.A., Figarella-Branger, D., Hawkins, C.,
621 Ng, H.K., Pfister, S.M., Reifenberger, G., et al. (2021). The 2021 WHO Classification of Tumors


- 622 of the Central Nervous System: a summary. *Neuro. Oncol.* 23, 1231–1251.
- 623 Maciejowski, J., Li, Y., Bosco, N., Campbell, P.J., and de Lange, T. (2015). Chromothripsis and
624 Kataegis Induced by Telomere Crisis. *Cell* 163, 1641–1654.
- 625 Mack, S.C., and Taylor, M.D. (2017). Put away your microscopes: The ependymoma molecular
626 era has begun. *Curr. Opin. Oncol.* 29, 443.
- 627 McVey, M., and Lee, S.E. (2008). MMEJ repair of double-strand breaks (director’s cut): deleted
628 sequences and alternative endings. *Trends Genet.* 24, 529–538.
- 629 Molenaar, J.J., Koster, J., Zwijnenburg, D.A., van Sluis, P., Valentijn, L.J., van der Ploeg, I.,
630 Hamdi, M., van Nes, J., Westerman, B.A., van Arkel, J., et al. (2012). Sequencing of
631 neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. *Nature* 483, 589–
632 593.
- 633 Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D., Zou, X., Martincorena, I.,
634 Alexandrov, L.B., Martin, S., Wedge, D.C., et al. (2016). Landscape of somatic mutations in 560
635 breast cancer whole-genome sequences. *Nature* 534, 47–54.
- 636 Notta, F., Chan-Seng-Yue, M., Lemire, M., Li, Y., Wilson, G.W., Connor, A.A., Denroche, R.E.,
637 Liang, S.-B., Brown, A.M.K., Kim, J.C., et al. (2016). A renewed model of pancreatic cancer
638 evolution based on genomic rearrangement patterns. *Nature* 538, 378–382.
- 639 Ostrom, Q.T., de Blank, P.M., Kruchko, C., Petersen, C.M., Liao, P., Finlay, J.L., Stearns, D.S.,
640 Wolff, J.E., Wolinsky, Y., Letterio, J.J., et al. (2015). Alex’s Lemonade Stand Foundation Infant
641 and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United
642 States in 2007–2011. *Neuro. Oncol.* 16, x1–x36.
- 643 Parker, M., Mohankumar, K.M., Punchihewa, C., Weinlich, R., Dalton, J.D., Li, Y., Lee, R.,
644 Tatevossian, R.G., Phoenix, T.N., Thiruvengatam, R., et al. (2014). C11orf95–RELA fusions
645 drive oncogenic NF- κ B signalling in ependymoma. *Nature* 506, 451–455.
- 646 Rausch, T., Zichner, T., Schlattl, A., Stütz, A.M., Benes, V., and Korbel, J.O. (2012a). DELLY:
647 structural variant discovery by integrated paired-end and split-read analysis. *Bioinformatics* 28,
648 i333–i339.
- 649 Rausch, T., Jones, D.T.W., Zapatka, M., Stütz, A.M., Zichner, T., Weischenfeldt, J., Jäger, N.,
650 Remke, M., Shih, D., Northcott, P.A., et al. (2012b). Genome sequencing of pediatric
651 medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. *Cell* 148, 59–71.
- 652 Shoshani, O., Brunner, S.F., Yaeger, R., Ly, P., Nechemia-Arbely, Y., Kim, D.H., Fang, R.,
653 Castillon, G.A., Yu, M., Li, J.S.Z., et al. (2020). Chromothripsis drives the evolution of gene
654 amplification in cancer. *Nature* 591, 137–141.
- 655 Singh, R., and Berger, B. (2021). Deciphering the species-level structure of topologically
656 associating domains. *BioRxiv* 2021.10.28.466333.
- 657 Steele, C.D., Abbasi, A., Islam, S.M.A., Bowes, A.L., Khandekar, A., Haase, K., Hames-Fathi,
658 S., Ajayi, D., Verfaillie, A., Dhimi, P., et al. (2022). Signatures of copy number alterations in
659 human cancer. *Nature* 606, 984–991.


- 660 Stephens, P.J., Greenman, C.D., Fu, B., Yang, F., Bignell, G.R., Mudie, L.J., Pleasance, E.D.,
661 Lau, K.W., Beare, D., Stebbings, L.A., et al. (2011). Massive genomic rearrangement acquired in
662 a single catastrophic event during cancer development. *Cell* *144*, 27–40.
- 663 Yang, L., Luquette, L.J., Gehlenborg, N., Xi, R., Haseley, P.S., Hsieh, C.-H., Zhang, C., Ren, X.,
664 Protopopov, A., Chin, L., et al. (2013). Diverse mechanisms of somatic structural variations in
665 human cancer genomes. *Cell* *153*, 919–929.
- 666 Zhang, C.-Z., Spektor, A., Cornils, H., Francis, J.M., Jackson, E.K., Liu, S., Meyerson, M., and
667 Pellman, D. (2015). Chromothripsis from DNA damage in micronuclei. *Nature* *522*, 179–184.
- 668 Zhang, F., Khajavi, M., Connolly, A.M., Towne, C.F., Batish, S.D., and Lupski, J.R. (2009). The
669 DNA replication FoSTeS/MMBIR mechanism can generate genomic, genic and exonic complex
670 rearrangements in humans. *Nat. Genet.* *41*, 849–853.
- 671 Zhang, J., Lee, D., Dhiman, V., Jiang, P., Xu, J., McGillivray, P., Yang, H., Liu, J., Meyerson,
672 W., Clarke, D., et al. (2020). An integrative ENCODE resource for cancer genomics. *Nat.*
673 *Commun.* *11*.
- 674 Zhang, Y., Chen, F., Donehower, L.A., Scheurer, M.E., and Creighton, C.J. (2021). A pediatric
675 brain tumor atlas of genes deregulated by somatic genomic rearrangement. *Nat. Commun.* *12*,
676 937.
- 677













A**B**

HGG (n=65)

